Taurine 3 pp 155-162 | Cite as

Taurine Inhibition of Iron-Stimulated Catecholamine Oxidation

  • Ralph DawsonJr.
  • Elisa Tang
  • Debbie Shih
  • Hunter Hern
  • Ming Hu
  • Deron Baker
  • Baerbel Eppler
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 442)

Abstract

Taurine (2-aminoethane sulfonic acid) is a sulfur containing amino acid that is present in mammalian tissues in millimolar concentrations10. Taurine is involved in a diverse array of biological functions which include: osmoregulation, membrane stabilization, neuromodulation, bile salt conjugation, and calcium modulation10. A role for taurine in cellular antioxidant defense mechanisms has been observed under a number of conditions3,17,21,25. Although taurine appears to have little intrinsic reactivity with oxidizing species1, its high concentration may still allow it to directly scavenge free radicals. Furthermore, taurine may bind reactive quinones involved in redox cycling and indirectly inhibit free radical formation11,22. Taurine could also moderate the effects of free radical damage by blunting the ability of prooxidants to increase intracellular free calcium10. The biosynthesis of taurine generates intermediates (hypotaurine and cysteamine) that also have free radical scavenging properties1,10,25. The synthesis of taurine also utilizes cysteine which is an excitatory amino acid that undergoes autoxidation reactions13. Taurine is present in tissues that contain high concentrations of catecholamines which are known to be cytotoxic and increase oxidative stress8,9,16,20. Taurine content declines in brain and peripheral tissues in aged rodents4. The age-related decline in tissue taurine content could increase the susceptibility of cells to free radical-mediated damage. Catecholamines are known to undergo autoxidation reactions to generate free radicals (H2O2, hydroxyl, superoxide) and cytotoxic quinones8,11,22. The oxidation of catecholamines is catalyzed by metals such as iron13. Iron-stimulated autoxidation of catecholamines is thought to play a role in neurodegenerative diseases26. One study has reported that chronic treatment with l-dopa caused a 13% decline in brain taurine content23. At present, it is unclear whether taurine under in vivo conditions serves as a scavenger for reactive quinones and free radicals derived from catecholamine autoxidation.

Keywords

Ferric Chloride Protein Carbonyl Carbonyl Content Protein Carbonyl Content Taurine Supplement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aruoma, O.I., Halliwell, B., Hoey, B.M., and Butler, J., 1988, The antioxidant action of taurine, hypotaurine and their metabolic precursors, Biochem. J., 256:251–255.PubMedGoogle Scholar
  2. 2.
    Carney, J.M., Starke-Reed, P.E., Oliver, C.N., Landum, R.W., Cheng, M.S., Wu, J.F., and Floyd, R.A., 1991, Reversal of age-related increases in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tertbutyl-α-phenylnitrone, Proc. Natl. Acad. Sci., 88:3633–3636.PubMedCrossRefGoogle Scholar
  3. 3.
    Cozzi, R., Ricordy, R., Bartolini, Ramadori, L., Perticone, P., and De Salvia, R., 1995, Taurine and ellagic acid: two differently-acting natural antioxidants, Environ. Mol. Mutagen., 26:248–254.PubMedCrossRefGoogle Scholar
  4. 4.
    Dawson, R. and Wallace, D.R., 1992, Taurine content in tissues from aged Fischer 344 rats, Age, 15:73–81.CrossRefGoogle Scholar
  5. 5.
    Dawson, R., Felheim, R. and Phillips, M.I., 1994, Characterization of the synthesis and release of dopamine in LLC-PK1 cells, Renal Physiol. Biochem., 17:85–100.PubMedGoogle Scholar
  6. 6.
    Dawson, R., Eppler, B., Patterson, T.A., Shih, D., and Liu, S., 1996, The effects of taurine in a rodent model of aging, in Adv. Exp. Med. Biol. “Taurine 2 Basic and Clinical Aspects”, Huxtable, R.J., Azuma, J., Kuriyama, K., Nakagawa, M., and Baba, A., eds., Plenum Press, Vol. 403, pp. 37-50.Google Scholar
  7. 7.
    Dean, R.T., Gieseg, S., and Davies, R.T., 1993, Reactive species and their accumulation on radical damaged proteins, Trends Biochem. Sci., 18:437–441.PubMedCrossRefGoogle Scholar
  8. 8.
    Graham, D.G., Tiffany, S.M., Bell, W.R., and Gutknecht, W.F., 1978, Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro, Mol. Pharmacol., 14:644–653.PubMedGoogle Scholar
  9. 9.
    Han, S-K., Mytilineou, C., and Cohen, G., 1996, L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress, J. Neurochem., 66:501–510.PubMedCrossRefGoogle Scholar
  10. 10.
    Huxtable, R.J., 1992, Physiological actions of taurine, Physiol. Rev., 72:101–163.PubMedGoogle Scholar
  11. 11.
    Kalyanaraman, B., Premovic, P.I., and Sealy, R.C., 1987, Semiquinone anion radicals from addition of amino acids, peptides, and proteins to quinones derived from oxidation of catechols and catecholamines, J. Biol. Chem., 262:11080–11087.PubMedGoogle Scholar
  12. 12.
    Levine, R.L, Garland, D., Oliver, C.N., Amici, A.A., Climent, I., Lenz, A., Ahn, B., Shaltiel, S., and Stadtman, E.R., 1990, Determination of carbonyl content in oxidatively modified proteins, Meth. Enzymol., 186:464–478.PubMedCrossRefGoogle Scholar
  13. 13.
    Miller, D.M., Buettner, G.R., and Aust, S.D., 1990, Transition metals as catalysts of “autoxidation” reactions, Free Rad. Biol. Med., 8:95–108.PubMedCrossRefGoogle Scholar
  14. 14.
    Monks, T.J. and Lau, S.S., 1992, Toxicology of quinone-thioethers, Crit. Rev. Toxicol., 22:243–270.PubMedCrossRefGoogle Scholar
  15. 15.
    Mosmann, T., 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Meth., 65:55–63.CrossRefGoogle Scholar
  16. 16.
    Pardo, B., Mena, M.A., Casarejos, M.J., Paino, C.L., and De Yebenes, J.G., 1995, Toxic effects of l-dopa on mesencephalic cell cultures: protection with antioxidants, Brain Res., 682:133–143.PubMedCrossRefGoogle Scholar
  17. 17.
    Pasantes-Morales, H., Wright, C.E., and Gaull, G.E., 1985, Taurine protection of lymphoblastoid cells from iron-ascorbate induced damage, Biochem. Pharmacol., 34:2205–2207.PubMedCrossRefGoogle Scholar
  18. 18.
    Spencer, J.P.E., Jenner, A., Aruoma, O.I., Evans, P.J., Kaur, H., Dexter, D.T., Jenner, P., Lees, A.J., Marsden, D.C., and Halliwell, B., 1994, Intense oxidative DNA damage promoted by l-dopa and its metabolites implications for neurodegenerative disease, FEBS Lett., 353:246–250.PubMedCrossRefGoogle Scholar
  19. 19.
    Stadtman, E.R. and Oliver, C.N., 1991, Metal-catalyzed oxidation of proteins, J. Biol. Chem., 266:2005–2008.PubMedGoogle Scholar
  20. 20.
    Tanaka, M., Sotomatsu, A., Kanai, H., and Hirai, S., 1991, Dopa and dopamine cause cultured neuronal death in the presence of iron, J. Neurol. Sci., 101:198–203.PubMedCrossRefGoogle Scholar
  21. 21.
    Trachtman, H., Futterwiet, S., and Bienkowski, R.S., 1993, Taurine prevents glucose-induced lipid peroxidation and increased collagen production in cultured rat mesangial cells, Biochem. Biophys. Res. Comm., 191:759–765.PubMedCrossRefGoogle Scholar
  22. 22.
    Tse, D.C.S., McCreery, R.L., and Adams, R., 1976, Potential oxidative pathways of brain catecholamines, J. Med. Chem., 19:37–40.PubMedCrossRefGoogle Scholar
  23. 23.
    Tyce, G.M. and Owen, C.A., 1973, The effect of L-3,4-dihydroxyphenylalanine administration on glucose metabolism in brain, J. Neurochem., 20:1563–1573.PubMedCrossRefGoogle Scholar
  24. 24.
    Wills, E.D., 1987, Evaluation of lipid peroxidation in lipids and biological membranes, in “Biochemical Toxicology a Practical Approach” Snell, K. and Mullock, B., eds., IRL Press, Oxford, pp. 127–152.Google Scholar
  25. 25.
    Wright, C.E., Tallan, H.H., Lin, Y.Y., and Gaull, G.E., 1986, Taurine: biological update, Ann. Rev. Biochem., 55:427–453.PubMedCrossRefGoogle Scholar
  26. 26.
    Youdim, M.B.H., Ben-Shachar, D., Eshel, G., Finberg, J.P.M., and Riederer, P., 1993, The neurotoxicity of iron and nitric oxide relevance to the etiology of Parkinson’s disease, Adv. Neurol., 60:259–265.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Ralph DawsonJr.
    • 1
  • Elisa Tang
    • 1
  • Debbie Shih
    • 1
  • Hunter Hern
    • 1
  • Ming Hu
    • 1
  • Deron Baker
    • 1
  • Baerbel Eppler
    • 1
  1. 1.Department of Pharmacodynamics, College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations